Nicole Paulina Maria Ezendam

Nicole Paulina Maria Ezendam

Auto-generated profile, based on publicly available information

Nicole Paulina Maria Ezendam

The Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

13 August 2021 in Cancer
Verified
Journal Article
Open access
PDF file
BRBelle H. de Rooij
Belle H. de Rooij
SOSimone Oerlemans
Simone Oerlemans
KDKatrijn van Deun
Katrijn van Deun
FMFloortje Mols
Floortje Mols
KLKelly M. de Ligt
Kelly M. de Ligt
DSDounya Schoormans
Dounya Schoormans
Background: Research into the clustering of symptoms may improve the understanding of the underlying mechanisms that affect survivors' symptom burden. This study applied network analyses in a balanced sample of cancer survivors to 1) explore the clustering of symptoms and 2) assess differences in symptom clustering between cancer types, treatment regimens, and short‐term and long‐term survivors.Methods: This study used cross‐sectional survey data, collected between 2008 and 2018, from the population‐based Patient Reported Outcomes Following Initial Treatment and Long Term Evaluation of Survivorship registry, which included survivors of 7 cancer types (colorectal cancer, breast cancer, ovarian cancer, thyroid cancer, chronic lymphocytic leukemia, Hodgkin lymphoma, and non‐Hodgkin lymphoma). Regularized partial correlation network analysis was used to explore and visualize the associations between self‐reported symptoms (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire) and the centrality of these symptoms in the network (ie, how strongly a symptom was connected to other symptoms) for the total sample and for subgroups separately.Results: In the total sample (n = 1330), fatigue was the most central symptom in the network with moderate direct relationships with emotional symptoms, cognitive symptoms, appetite loss, dyspnea, and pain. These relationships persisted after adjustments for sociodemographic and clinical characteristics. Connections between fatigue and emotional symptoms, appetite loss, dyspnea, and pain were consistently found across all cancer types (190 for each), treatment regimens, and short‐term and long‐term survivors.Conclusions: In a heterogenous sample of cancer survivors, fatigue was consistently the most central symptom in all networks. Although longitudinal data are needed to build a case for the causal nature of these symptoms, cancer survivorship rehabilitation programs could focus on fatigue to reduce the overall symptom burden.

2 September 2016 in Journal of Ovarian Research
Verified
Journal Article
Open access
PDF file
MVMaria Caroline Vos
Maria Caroline Vos
EHEva Hollemans
Eva Hollemans
NENicole Ezendam
Nicole Ezendam
HFHarry Feijen
Harry Feijen
DBDorry Boll
Dorry Boll
LMLeon F. A. G. Massuger
Leon F. A. G. Massuger
To investigate the expression of MMP-14 and CD44 as well as epithelial-to-mesenchymal transition(EMT)-like changes in ovarian cancer and to determine correlations with clinical outcome. In 97 patients with ovarian cancer, MMP-14 and CD44 expression as determined by immunohistochemistry was investigated in relation to EMT-like changes. To determine this, immunohistochemical staining of E-cadherin and vimentin was performed. Patients with expression of both MMP-14 and CD44 in their tumors had a poor prognosis despite complete debulking. Serous histology in advanced-stage tumors (FIGO IIB-IV) correlated with CD44 (rho .286, p < 0.01). Also, CD44 correlated with percentage vimentin expression (rho .217, p < 0.05). In logistic regression analysis with complete debulking as the outcome parameter, CD44 expression was found to be significant (OR 3,571 (95 % Confidence Interval 1,112–11,468) p = 0.032), though this was not the case for MMP-14 and EMT parameters. The subgroup of patients with double expression of MMP-14 and CD44 had a poor prognosis despite complete debulking. Serous subtype in advanced-stage patients and CD44 expression were found to be correlated with vimentin expression, and CD44 expression was found to be significantly correlated with complete debulking. However, a significant correlation between EMT and clinical parameters was not found.

28 May 2014 in Journal of Cancer Survivorship
Verified
Journal Article
Closed access
PDF file
NENicole P. M. Ezendam
Nicole P. M. Ezendam
KNKim A. H. Nicolaije
Kim A. H. Nicolaije
RKRoy Kruitwagen
Roy Kruitwagen
JPJohanna Pijnenborg
Johanna Pijnenborg
MVM. Caroline Vos
M. Caroline Vos
LPLonneke V. van de Poll-Franse
Lonneke V. van de Poll-Franse

22 April 2019 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
SASalome Adam
Salome Adam
LPLonneke V. van de Poll‐Franse
Lonneke V. van de Poll‐Franse
FMFloortje Mols
Floortje Mols
NENicole P. M. Ezendam
Nicole P. M. Ezendam
IHIgnace de Hingh
Ignace de Hingh
MTMelissa Thong
Melissa Thong
Purpose: Cancer‐related fatigue (CRF) is one of the most prevalent symptoms experienced by cancer survivors. However, researchers are only beginning to elucidate the risk factors, underlying mechanism(s), and its association with other outcomes. Research on the association between CRF and mortality is limited.Methods: The study sample comprised 2059 short‐term (<5 years postdiagnosis) cancer survivors from four PROFILES registry studies. Survivors diagnosed with stage I‐III colorectal cancer (CRC) or stage I‐III endometrial cancer (EC), with no evidence of disease, were identified and followed‐up by the Netherlands Cancer Registry. Fatigue was assessed with the Fatigue Assessment Scale. Cox proportional hazards models adjusted for demographic, clinical, and lifestyle characteristics were performed to assess the association of CRF with all‐cause mortality. Date of censoring was February 1, 2017.Results: Prevalence of CRF varied between 35.8% (male CRC) and 43.6% (female CRC). After a median follow‐up period of 9.0 years, a total of 408 survivors (20%) had died. CRF was associated with increased all‐cause mortality in male CRC survivors (HRadj = 1.75, 95% CI [1.31‐2.33]). This association remained statistically significant after excluding survivors experiencing anhedonia. For female CRC (HRadj = 1.32, 95% CI [0.90‐1.97]) and EC (HRadj = 1.27, 95% CI [0.84‐1.90]) survivors, there was no significant association with all‐cause mortality for the fatigued group in multivariable analyses.Conclusion: Our study found that CRF is significantly associated with all‐cause mortality in male CRC survivors, irrespective of potential confounders. This result suggests that clinicians should increase their attention towards the recognition and treatment of CRF.

1 June 2014 in Patient Education and Counseling
Verified
Journal Article
Closed access
MVMariëtte N. Verkissen
Mariëtte N. Verkissen
NENicole P.M. Ezendam
Nicole P.M. Ezendam
MFMirjam Fransen
Mirjam Fransen
MEMarie-Louise Essink-Bot
Marie-Louise Essink-Bot
MAMieke J. Aarts
Mieke J. Aarts
Olga HussonOlga Husson
Olga Husson